NCT00957047View on ClinicalTrials.gov

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

PHASE3CompletedINTERVENTIONAL
Enrollment

395

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

January 31, 2008

Conditions
Partial Epilepsy
Interventions
DRUG

eslicarbazepine acetate

oral tablets

DRUG

placebo

once daily placebo comparator

DRUG

ESL - Part II

Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.

Trial Locations (1)

4745-457

Bial - Portela & Cª, S.A., Trofa

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT00957047 - Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy | Biotech Hunter | Biotech Hunter